



DEPARTMENT OF HEALTH & HUMAN SERVICES

Public Health Service

Food and Drug Administration  
Rockville, MD 20857

NDA 19-201/S-035  
NDA 20-142/S-017  
NDA 20-254/S-016

Novartis Pharmaceuticals Corporation  
One Health Plaza  
East Hanover, NJ 07936-1080

Attention: Roxanne Tavakkol  
Associate Director, Drug Regulatory Affairs

Dear Ms. Tavakkol:

Please refer to your supplemental new drug applications dated July 28, 2005, received July 29, 2005, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act for the following products:

NDA #	Supplement #	Drug
19-201	S-035	Voltaren® (diclofenac sodium) Enteric-coated Tablets
20-142	S-017	Cataflam® (diclofenac potassium) Tablets
20-254	S-016	Voltaren-XR® (diclofenac sodium) Tablets

We acknowledge receipt of your submission dated December 19, 2005 for Voltaren (diclofenac sodium) Enteric-coated Tablets.

These “Changes Being Effected in 30 days” supplemental new drug applications were submitted in response to the Agency’s letter dated June 14, 2005, requiring class labeling language for all non-selective non-steroidal anti-inflammatory drugs (NSAIDS), to include a boxed warning to address possible cardiovascular risks as well as known gastrointestinal risks, revised **CONTRAINDICATIONS, WARNINGS** and **PRECAUTIONS** sections of the package insert, and a **MedGuide** for NSAIDS.

We have completed our review of these applications, as amended, and they are approved, effective on the date of this letter, for use as recommended in the agreed-upon labeling text.

The final printed labeling (FPL) must be identical, and include the revisions indicated, to the enclosed labeling text for the package insert and the MedGuide. The revisions were agreed upon during a December 1, 2005 teleconference. These revisions are terms of the approval of this application.

Please submit an electronic version of the FPL according to the guidance for industry titled *Providing Regulatory Submissions in Electronic Format - NDA*. Alternatively, you may submit 20 paper copies of the FPL as soon as it is available but no more than 30 days after it is printed. Individually mount 15 of the copies on heavy-weight paper or similar material. For administrative purposes, designate this

submission "**FPL for approved supplement NDAs 19-201/S-035, 20-142/S-017, and 20-254/S-016.**" Approval of this submission by FDA is not required before the labeling is used.

If you issue a letter communicating important information about these drug products (i.e., a "Dear Health Care Professional" letter), we request that you submit a copy of the letter to this NDA and a copy to the following address:

MEDWATCH  
Food and Drug Administration  
WO 22, Room 4447  
10903 New Hampshire Avenue  
Silver Spring, MD 20993-0002

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

If you have any questions, call Paul Balcer, Regulatory Project Manager, at (301) 796-1173.

Sincerely,

*{See appended electronic signature page}*

Bob Rappaport, M.D.  
Director  
Division of Anesthesia, Analgesia and  
Rheumatology Products  
Office of Drug Evaluation II  
Center for Drug Evaluation and Research

Enclosure

-----  
**This is a representation of an electronic record that was signed electronically and  
this page is the manifestation of the electronic signature.**  
-----

/s/

-----  
Bob Rappaport  
1/24/2006 05:36:57 PM